GlobeImmune Financial Statements From 2010 to 2026
| GBIM Stock | USD 0.0001 0.00 0.00% |
Check GlobeImmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlobeImmune's main balance sheet or income statement drivers, such as , as well as many indicators such as . GlobeImmune financial statements analysis is a perfect complement when working with GlobeImmune Valuation or Volatility modules.
GlobeImmune |
GlobeImmune Company Profit Margin Analysis
GlobeImmune's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current GlobeImmune Profit Margin | (0.33) % |
Most of GlobeImmune's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlobeImmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, GlobeImmune has a Profit Margin of -0.333%. This is 97.03% lower than that of the Biotechnology sector and 98.55% lower than that of the Health Care industry. The profit margin for all United States stocks is 73.78% lower than that of the firm.
GlobeImmune Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GlobeImmune's current stock value. Our valuation model uses many indicators to compare GlobeImmune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GlobeImmune competition to find correlations between indicators driving GlobeImmune's intrinsic value. More Info.GlobeImmune is rated # 3 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GlobeImmune's earnings, one of the primary drivers of an investment's value.About GlobeImmune Financial Statements
GlobeImmune investors utilize fundamental indicators, such as revenue or net income, to predict how GlobeImmune Pink Sheet might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. GlobeImmune, Inc. operates as a subsidiary of ImmunityBio, Inc. Globeimmune operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in GlobeImmune Pink Sheet
GlobeImmune financial ratios help investors to determine whether GlobeImmune Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlobeImmune with respect to the benefits of owning GlobeImmune security.